Skip to main content Accessibility help
×
Home
Hostname: page-component-684899dbb8-mhx7p Total loading time: 0.584 Render date: 2022-05-29T09:58:17.598Z Has data issue: true Feature Flags: { "shouldUseShareProductTool": true, "shouldUseHypothesis": true, "isUnsiloEnabled": true, "useRatesEcommerce": false, "useNewApi": true }

Anti-diabetic and hypoglycaemic effects of Momordica charantia (bitter melon): a mini review

Published online by Cambridge University Press:  13 October 2009

Lawrence Leung*
Affiliation:
Department of Family Medicine, Centre for Studies in Primary Care, Queen's University, 220 Bagot Street PO Bag 8888, Kingston, ONK7L 5E9, Canada
Richard Birtwhistle
Affiliation:
Department of Family Medicine, Centre for Studies in Primary Care, Queen's University, 220 Bagot Street PO Bag 8888, Kingston, ONK7L 5E9, Canada
Jyoti Kotecha
Affiliation:
Department of Family Medicine, Centre for Studies in Primary Care, Queen's University, 220 Bagot Street PO Bag 8888, Kingston, ONK7L 5E9, Canada
Susan Hannah
Affiliation:
Department of Family Medicine, Centre for Studies in Primary Care, Queen's University, 220 Bagot Street PO Bag 8888, Kingston, ONK7L 5E9, Canada
Sharon Cuthbertson
Affiliation:
Department of Family Medicine, Centre for Studies in Primary Care, Queen's University, 220 Bagot Street PO Bag 8888, Kingston, ONK7L 5E9, Canada
*
*Corresponding author: Dr Lawrence Leung, fax +1 613 544 9899, email leungl@queensu.ca
Rights & Permissions[Opens in a new window]

Abstract

It has been estimated that up to one-third of patients with diabetes mellitus use some form of complementary and alternative medicine. Momordica charantia (bitter melon) is a popular fruit used for the treatment of diabetes and related conditions amongst the indigenous populations of Asia, South America, India and East Africa. Abundant pre-clinical studies have documented the anti-diabetic and hypoglycaemic effects of M. charantia through various postulated mechanisms. However, clinical trial data with human subjects are limited and flawed by poor study design and low statistical power. The present article reviews the clinical data regarding the anti-diabetic potentials of M. charantia and calls for better-designed clinical trials to further elucidate its possible therapeutic effects.

Type
Review Article
Copyright
Copyright © The Authors 2009

Diabetes mellitus is a major global health concern with a projected rise in prevalence from 171 million in 2000 to 366 million in 2030(Reference Wild, Roglic and Green1). Diabetes mellitus is characterised by chronic hyperglycaemia and postprandial hyperglycaemia, both leading to enhanced micro- and macrovascular morbidity and overall mortality(Reference Balkau2Reference Ceriello3). Amongst ethnic minorities, cultural beliefs about diabetes mellitus often differ and may compromise adherence to therapy(Reference Chia, Schlenk and Dunbar-Jacob4Reference Ryan, Pick and Marceau6). Complementary and alternative medicine involves the use of herbs and other dietary supplements as alternatives to mainstream Western medical treatment. A recent study has estimated that up to 30 % of patients with diabetes mellitus use complementary and alternative medicine(Reference Ryan, Pick and Marceau6). Momordica charantia (MC), also known as bitter melon, karela, balsam pear, or bitter gourd, is a popular plant used for the treating of diabetes-related conditions amongst the indigenous populations of Asia, South America, India, the Caribbean and East Africa(Reference Grover and Yadav7Reference Cefalu, Ye and Wang10). MC is a tendril-bearing vine belonging to the Cucurbitaceae family. It is a climbing perennial that usually grows up to 5 m, and bears elongated fruits with a knobbly surface. MC fruit has a distinguishing bitter taste, which is more pronounced as it ripens, hence the name bitter melon or bitter gourd.

Biochemical and animal model experiments have produced abundant data and hypotheses accounting for the anti-diabetic effects of MC. In comparison, clinical studies with human subjects are sparse and low quality in design. The authors reviewed the available data regarding the hypoglycaemic effects of MC in human subjects searching the PubMed and EMBASE for articles published in English with the following key words: ‘Mormodica’, ‘Momordica charantia’, ‘bitter melon’, ‘bitter gourd’, ‘hypoglycaemic’, ‘anti-diabetic’ and ‘human’.

Phytochemistry of Momordica charantia

Of the MC fruit, 93·2 % is composed of water, while protein and lipids account for 18·02 and 0·76 % of its dried weight(Reference Yuwai, Rao and Kaluwin11). On the contrary, nearly 45 % of the MC seed is composed of oils which contain 63–68 % eleostearic acid and 22–27 % stearic acid(Reference Chang, Conkerton and Chapital12). Several glycosides have been isolated from the MC stem(Reference Chang, Chen and Liao13) and MC fruit(Reference Harinantenaina, Tanaka and Takaoka14Reference Tan, Ye and Turner16) and are grouped under the genera of cucurbitane-type triterpenoids. In particular, four triterpenoids have AMP-activated protein kinase activity which is a plausible hypoglycaemic mechanism of MC(Reference Tan, Ye and Turner16).

Animal studies of Momordica charantia

Various animal studies have repeatedly shown hypoglycaemic effects of the seeds, fruit pulp, leaves and whole plant of MC in normal animals(Reference Day, Cartwright and Provost17Reference Jayasooriya, Sakono and Yukizaki21). In particular, MC improves glucose tolerance(Reference Leatherdale, Panesar and Singh22) and suppresses postprandial hyperglycaemia in rats(Reference Uebanso, Arai and Taketani23), and MC extract can enhance insulin sensitivity and lipolysis(Reference Chen, Chan and Li24, Reference Chen and Li25). Some studies also claimed that the hypoglycaemic effect of MC was comparable with oral medications such as tolbutamide(Reference Sarkar, Pranava and Marita20), chlorpropamide(Reference Ojewole, Adewole and Olayiwola26) and glibenclamide(Reference Virdi, Sivakami and Shahani27).

Abundant biochemical data have shed light upon possible mechanisms of the anti-diabetic actions of MC with the recurring theme being activation of the AMP-activated protein kinase system(Reference Miura, Itoh and Iwamoto28Reference Cheng, Huang and Chang31). Other studies suggested a role of the α- and γ-peroxisome proliferator-activated receptors (PPARα and PPARγ) which are pivotal in lipid and glucose haemostasis and may mitigate insulin resistance(Reference Chuang, Hsu and Chao32Reference Shih, Lin and Lin34). Recently, a Zn-free protein bearing insulinomimetic activities was isolated from MC(Reference Yibchok-Anun, Adisakwattana and Yao35) that echoed the idea of ‘vegetable insulin’ isolated by Baldwa et al. (Reference Baldwa, Bhandari and Pangaria36) some 30 years ago.

Clinical studies of Momordica charantia

Compared with animal studies, clinical studies regarding the hypoglycaemic effects of MC have been sparse and sporadic. Lakholia, a physician, was probably the first to document the therapeutic effect of bitter melon in 1956 using himself as the subject(Reference Lakholia37). As we reviewed the studies fulfilling our search criteria, we noticed that the majority lacked proper controls or suffered from poor methodologies without baseline characterisations(Reference Leatherdale, Panesar and Singh22, Reference Baldwa, Bhandari and Pangaria36, Reference Srivastava, Venkatakrishna-Bhatt and Verma38Reference Dans, Villarruz and Jimeno48), as tabulated in Table 1. Amongst those, five have been selected for further discussion as follows. Four were designed as clinical trials and the fifth study, albeit a case series, was selected due to its large sample size.

Table 1 Clinical studies of Momordica charantia (MC)

T2D, type 2 diabetes; DM, diabetes mellitus; OGTT, oral glucose tolerance test; T1D, type 1 diabetes.

John et al. study

John et al. (Reference John, Cherian and Subhash46) randomised fifty subjects (twenty-six trials and twenty-four controls) with type 2 diabetes (T2D) to receive either dried MC fruit or riboflavin. Clear inclusion criteria based on fasting blood sugar (FBS) and postprandial sugar (PPS) levels were adopted. Sample size was calculated using a targeted reduction of sugar level by 300 mg/l (30 mg/dl) for both FBS and PPS. Baseline characteristics of all subjects were all comparable. Dried MC fruit was administered at a dose of 2 g three times per d, and riboflavin was employed as the placebo. All subjects were instructed to maintain their pre-existing oral hypoglycaemic treatment and dietary patterns. FBS and PPS levels were measured with fructosamine levels at baseline before treatment, at 2 weeks, and at 4 weeks post-treatment. Results did not show a statistically significant effect due to intervention, for which the authors ascribed to the possible use of dried MC rather than fresh fruit, or due to a suboptimal dose. In this study, there was no mention of the randomisation protocol; nor was it a double-blind design due to the non-matching placebo. Also, the authors only mentioned the lack of adverse effects, but did not account for dropouts. The Jadad score(Reference Jadad, Moore and Carroll49) for this randomised study is, therefore, 1 (from a score of 0 to 5).

Dans et al. study

Dans et al. (Reference Dans, Villarruz and Jimeno48) conducted a randomised double-blind placebo-controlled trial with forty subjects who were either newly diagnosed or poorly controlled T2D having HbA1c levels between 7 and 9 %. Sample size was calculated using a targeted reduction of 1 % in HbA1c and estimated power of study at 0·88. Baseline characteristics of all subjects were not significantly different. A brand-name product containing a standardised dose of dried MC extract was given to the trial group at the dose of two capsules three times per d (exact amount per capsule unknown), for a period of 3 months. The control group followed the same protocol except taking a matching placebo. Baseline HbA1c and other biochemical tests were performed before initiating treatment. Subjects were then followed-up monthly for 3 months, where blood sugars were measured and compliance or adverse effects were noted. At the end of treatment, all baseline tests were repeated. Results showed a mean reduction of 0·217 % in HbA1c in the trial group, which was not statistically significant (P = 0·483) and not sufficient to reject the null hypothesis. As a conclusion, the authors suggested a repeat study with a larger sample size. Nevertheless, this study is merited for its proper design, adverse effects were clearly documented, and dropouts were individually accounted for. The Jadad score for this study is, therefore, 5.

Tongia et al. study

Tongia et al. (Reference Tongia, Tongia and Dave47) recruited fifteen subjects with T2D and divided them into three equal groups. Apart from diagnostic label and age, inclusion criteria were not defined. FBS and PPS levels were measured in subjects before intervention, and these data were then used as controls. The three groups then received metformin, glibenclamide, and metformin+glibenclamide, respectively, for 7 d before the FBS and PPS values were measured. In the next 7 d, subjects received oral hypoglycaemic medications at half dose, plus a standard dose of MC fruit extract twice per d (given in the dose of 200 mg twice daily) and FBS and PPS levels were measured again. Results showed reductions in both FBS and PPS levels after oral hypoglycaemics and a further reduction with MC extract. The quoted P values, although significant, have to be considered against the small sample size of fifteen subjects. Worth noting is that this study used a within-subject design and there was no clear mention of the inclusion criteria. In addition, there was no justification of the sample size and study power. As this study is not a randomised trial, it cannot be rated with a Jadad score.

Baldwa et al. study

Baldwa et al. (Reference Baldwa, Bhandari and Pangaria36) recruited fourteen diabetic subjects (type 1 diabetes (T1D) and T2D) with five healthy volunteers and investigated the effect of an insulin-like substance extracted from MC fruit that was coined the ‘vegetable insulin’. Nine diabetic subjects received subcutaneous injection of the ‘vegetable insulin’ according to a sliding scale (exact dosage not mentioned). Five other diabetic patients together with five healthy volunteers acted as controls and received a placebo injection (nature of placebo not mentioned). In the trial group, there was a 21·5 % reduction in blood glucose at 30 min, 49·2 % reduction at 4 h and 28 % reduction at 12 h, as compared with pre-injection levels. Those who received placebo showed a 5 % decrease in glucose level irrespective of whether they were diabetic or healthy controls. Despite the significant results, this study suffered methodological limitations. There was no clear randomisation protocol; investigators and subjects were not blinded; baseline characteristics of the subjects were not uniform, either in their pathology (both T1D and T2D in the trial group), or their severity (baseline glucose levels varied from 2100 to 2950 g/l (210 to 295 mg/dl)). In addition, the control arm was also heterogeneous (both healthy and diabetic patients). Again, this is not a randomised trial and cannot be rated with a Jadad score.

Ahmad et al. study

Ahmad et al. (Reference Ahmad, Hassan and Halder44) studied the effect of MC in a case series of 100 T2D subjects (fifty-eight males and forty-two females). The inclusion criteria were explicit and baseline characteristics of all subjects were statistically comparable. Subjects were instructed to stop their existing oral medications for 3 d before the trial as a washout. Fasting (s1) and postprandial blood sugar (s2) levels were measured on day 1. On day 2, fasting blood sugar was measured again (s3), and all subjects ingested a drink made from freshly blended MC fruit (dosage varied according to the body weight of subjects). Blood sugar was measured 1 h (s4) afterwards, followed by a postprandial measurement in another 2 h (s5). The control groups were s1, s2 and s3 as compared with the trial groups of s4 and s5. Results showed an 18 % mean reduction both in fasting and postprandial sugar levels across 86 % of all subjects. Despite the good sample size, this study used the same subjects as controls and trials. There was no mention of adverse effects or dropouts, although the authors did discuss limitations, such as lack of supervision for subjects to carry out instructions at home. Therefore, this study showed a flawed methodological design. Being a case series, it cannot be rated with the Jadad score.

It is evident that in these five studies, the forms of MC administration (from methanol extract, dried powder to fresh fruit), the actual dosage (timing and dose per kg body weight) and the outcome measures (from HbA1c, postprandial sugar levels to oral glucose tolerance test) differ widely. Therefore, it is impossible to do any meta-analysis or between-study analyses. For ease of administration, it would be best for MC to be taken in encapsulated powder; however, the available studies seemed to point to a better efficacy for MC when taken in fresh or juiced form(Reference Srivastava, Venkatakrishna-Bhatt and Verma38, Reference Welihinda, Karunanayake and Sheriff42, Reference Ahmad, Hassan and Halder44, Reference John, Cherian and Subhash46). Moreover, available data seem to support an acute or a single dose effect(Reference Baldwa, Bhandari and Pangaria36, Reference Khanna, Jain and Panagariya40, Reference Welihinda, Karunanayake and Sheriff42Reference Ahmad, Hassan and Halder44) of MC rather than a long-term effect of longer than 4 weeks(Reference Patel, Dhirawani and Doshi39, Reference John, Cherian and Subhash46, Reference Dans, Villarruz and Jimeno48). In order to evaluate the hypoglycaemic effects of MC, the authors suggest a well-designed randomised controlled clinical trial with good sample size for sufficient power. It will employ multiple arms (fresh MC juice, dried MC powder and corresponding matching placebos) with cross-over and washout, to be conducted over a period of 6–12 months with interim analysis.

Toxicity and side effects

At the time of writing the present review, there were no large-scale studies found that examined the side-effects of MC, but the years of its consumption as a dietary supplement and ethnomedicine in various countries do suggest a high level of safety. Having said, there have been isolated reports of hypoglycaemic comas in children after drinking bitter melon tea(Reference Hulin50, Reference Raman51), and one report of death due to consumption of bitter melon fruit(Reference Heiser52). The MC seeds contain a lectin which can inhibit protein synthesis in the intestinal walls of an animal model(Reference Stepka53), but they produce no gastrointestinal symptoms in humans, except for a report of headache(Reference Raman51). MC seeds may also induce favism in humans with glucose-6 phosphate dehydrogenase deficiency(Reference Raman51), while in animals, MC fruit can lead to depressed fertility(Reference Stepka53Reference Dixit, Khanna and Bhargava55) and induction of abortions(Reference Chan, Tam and Yeung56, Reference Leung, Yeung and Leung57). In the study by Dans et al. (Reference Dans, Villarruz and Jimeno48), gastrointestinal symptoms such as abdominal discomfort and diarrhoea have been reported.

Conclusion

The concept of food as medicine is a central theme in dietetic and nutritional sciences. MC has been used as dietary supplements and ethnomedicine throughout centuries for relieving symptoms and conditions related to what we know in modern days as diabetes. Despite the abundant data from biochemical and animal studies, available clinical data as reviewed in the present article are often flawed by small sample size, lack of control and poor study designs. The present review supports the need for better-designed clinical trials with sufficient sample size and statistical power to further vindicate the acclaimed efficacy of MC as a natural nutritional treatment for diabetes mellitus. In particular, MC may be a feasible option for ethnic minorities who have a high prevalence of diabetes but prefer treatment based on natural products according to their cultural beliefs.

Acknowledgements

The present study received no specific grant from any funding agency in the public, commercial or not-for-profit sectors.

L. L. wrote the manuscript. L. L., R. B. and S. C. discussed the draft. J. K and S. H. assisted in the literature search and final revision.

There has been no conflict of interest.

References

1Wild, S, Roglic, G, Green, A, et al. (2004) Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care 27, 10471053.CrossRefGoogle ScholarPubMed
2Balkau, B (2000) The DECODE study. Diabetes epidemiology: collaborative analysis of diagnostic criteria in Europe. Diabetes Metab 26, 282286.Google Scholar
3Ceriello, A (2005) Postprandial hyperglycemia and diabetes complications: is it time to treat? Diabetes 54, 17.CrossRefGoogle ScholarPubMed
4Chia, LR, Schlenk, EA & Dunbar-Jacob, J (2006) Effect of personal and cultural beliefs on medication adherence in the elderly. Drugs Aging 23, 191202.CrossRefGoogle ScholarPubMed
5Shane-McWhorter, L & Oderda, LH (2007) Importance of cultural issues in managing a patient with diabetes. Consult Pharm 22, 431437.CrossRefGoogle ScholarPubMed
6Ryan, EA, Pick, ME & Marceau, C (2001) Use of alternative medicines in diabetes mellitus. Diabet Med 18, 242245.CrossRefGoogle ScholarPubMed
7Grover, JK & Yadav, SP (2004) Pharmacological actions and potential uses of Momordica charantia: a review. J Ethnopharmacol 93, 123132.CrossRefGoogle ScholarPubMed
8Abascal, K & Yarnell, E (2005) Using bitter melon to treat diabetes. J Altern Complement Med 1, 179184.Google Scholar
9Lans, CA (2006) Ethnomedicines used in Trinidad and Tobago for urinary problems and diabetes mellitus. J Ethnobiol Ethnomed 2, 45.CrossRefGoogle ScholarPubMed
10Cefalu, WT, Ye, J & Wang, ZQ (2008) Efficacy of dietary supplementation with botanicals on carbohydrate metabolism in humans. Endocr Metab Immune Disord Drug Targets 8, 7881.CrossRefGoogle ScholarPubMed
11Yuwai, KE, Rao, KS, Kaluwin, C, et al. (1991) Chemical composition of Momordica charantia L. fruits. J Agric Food Chem 39, 17621763.CrossRefGoogle Scholar
12Chang, MK, Conkerton, EJ, Chapital, DC, et al. (1996) Chinese melon (Momordica charantia L.) seed: composition and potential use. J Am Oil Chem Soc 73, 263265.CrossRefGoogle Scholar
13Chang, CI, Chen, CR, Liao, YW, et al. (2006) Cucurbitane-type triterpenoids from Momordica charantia. J Nat Prod 71, 13271330.CrossRefGoogle Scholar
14Harinantenaina, L, Tanaka, M, Takaoka, S, et al. (2006) Momordica charantia constituents and antidiabetic screening of the isolated major compounds. Chem Pharm Bull (Tokyo) 54, 10171021.CrossRefGoogle ScholarPubMed
15Li, QY, Chen, HB, Liu, ZM, et al. (2007) Cucurbitane triterpenoids from Momordica charantia. Magn Reson Chem 45, 451456.CrossRefGoogle ScholarPubMed
16Tan, MJ, Ye, JM, Turner, N, et al. (2008) Antidiabetic activities of triterpenoids isolated from bitter melon associated with activation of the AMPK pathway. Chem Biol 15, 263273.CrossRefGoogle ScholarPubMed
17Day, C, Cartwright, T, Provost, J, et al. (1990) Hypoglycaemic effect of Momordica charantia extracts. Planta Med 56, 426429.CrossRefGoogle ScholarPubMed
18Shibib, BA, Khan, LA & Rahman, R (1993) Hypoglycaemic activity of Coccinia indica and Momordica charantia in diabetic rats: depression of the hepatic gluconeogenic enzymes glucose-6-phosphatase and fructose-1,6-bisphosphatase and elevation of both liver and red-cell shunt enzyme glucose-6-phosphate dehydrogenase. Biochem J 15, 267270.CrossRefGoogle Scholar
19Ali, L, Khan, AK, Mamun, MI, et al. (1993) Studies on hypoglycemic effects of fruit pulp, seed, and whole plant of Momordica charantia on normal and diabetic model rats. Planta Med 59, 408412.CrossRefGoogle ScholarPubMed
20Sarkar, S, Pranava, M & Marita, R (1996) Demonstration of the hypoglycemic action of Momordica charantia in a validated animal model of diabetes. Pharmacol Res 33, 14.CrossRefGoogle Scholar
21Jayasooriya, AP, Sakono, M, Yukizaki, C, et al. (2000) Effects of Momordica charantia powder on serum glucose levels and various lipid parameters in rats fed with cholesterol-free and cholesterol-enriched diets. J Ethnopharmacol 72, 331336.CrossRefGoogle ScholarPubMed
22Leatherdale, BA, Panesar, RK, Singh, G, et al. (1981) Improvement in glucose tolerance due to Momordica charantia (karela). BMJ 282, 18231824.CrossRefGoogle Scholar
23Uebanso, T, Arai, H, Taketani, Y, et al. (2007) Extracts of Momordica charantia suppress postprandial hyperglycemia in rats. J Nutr Sci Vitaminol (Tokyo) 53, 482488.CrossRefGoogle ScholarPubMed
24Chen, Q, Chan, LL & Li, ET (2003) Bitter melon (Momordica charantia) reduces adiposity, lowers serum insulin and normalizes glucose tolerance in rats fed a high fat diet. J Nutr 133, 10881093.CrossRefGoogle ScholarPubMed
25Chen, Q & Li, ET (2005) Reduced adiposity in bitter melon (Momordica charanita) fed rats is associated with lower tissue triglyceride and higher plasma catecholamines. Br J Nutr 93, 747754.CrossRefGoogle ScholarPubMed
26Ojewole, JA, Adewole, SO & Olayiwola, G (2006) Hypoglycaemic and hypotensive effects of Momordica charantia Linn (Cucurbitaceae) whole-plant aqueous extract in rats. Cardiovasc J S Afr 17, 227232.Google ScholarPubMed
27Virdi, J, Sivakami, S, Shahani, S, et al. (2003) Antihyperglycemic effects of three extracts from Momordica charantia. J Ethnopharmacol 88, 107111.CrossRefGoogle ScholarPubMed
28Miura, T, Itoh, C, Iwamoto, N, et al. (2001) Hypoglycemic activity of the fruit of the Momordica charantia in type 2 diabetic mice. J Nutr Sci Vitaminol (Tokyo) 47, 340.CrossRefGoogle ScholarPubMed
29Zheng, D, MacLean, PS, Pohnert, SC, et al. (2001) Regulation of muscle GLUT-4 transcription by AMP-activated protein kinase. J Appl Physiol 91, 10731083.CrossRefGoogle ScholarPubMed
30McCarty, MF (2004) Does bitter melon contain an activator of AMP-activated kinase? Med Hypotheses 63, 340343.CrossRefGoogle ScholarPubMed
31Cheng, HL, Huang, HK, Chang, CI, et al. (2008) A cell-based screening identifies compounds from the stem of Momordica charantia that overcome insulin resistance and activate AMP-activated protein kinase. J Agric Food Chem 27, 68356843.CrossRefGoogle Scholar
32Chuang, CY, Hsu, C, Chao, CY, et al. (2006) Fractionation and identification of 9c, 11t, 13t-conjugated linolenic acid as an activator of PPARα in bitter gourd (Momordica charantia L.). J Biomed Sci 13, 763772.CrossRefGoogle Scholar
33Huang, HL, Hong, YW, Wong, YH, et al. (2008) Bitter melon (Momordica charantia L.) inhibits adipocyte hypertrophy and down regulates lipogenic gene expression in adipose tissue of diet-induced obese rats. Br J Nutr 99, 230239.CrossRefGoogle ScholarPubMed
34Shih, CC, Lin, CH & Lin, WL (2008) Effects of Momordica charantia on insulin resistance and visceral obesity in mice on high-fat diet. Diabetes Res Clin Pract 81, 134143.CrossRefGoogle ScholarPubMed
35Yibchok-Anun, S, Adisakwattana, S, Yao, CY, et al. (2006) Slow acting protein extract from fruit pulp of Momordica charantia with insulin secretagogue and insulinomimetic activities. Biol Pharm Bull 29, 11261131.CrossRefGoogle ScholarPubMed
36Baldwa, VS, Bhandari, CM, Pangaria, A, et al. (1977) Clinical trials in patients with diabetes mellitus of an insulin-like compound obtained from plant source. Ups J Med Sci 82, 3941.CrossRefGoogle ScholarPubMed
37Lakholia, AN (1956) The use of bitter gourd in diabetes mellitus. Antiseptic 53, 608610.Google Scholar
38Srivastava, Y, Venkatakrishna-Bhatt, H & Verma, Y (1993) Antidiabetic and adaptogenic properties of Momordica charantia extract: an experimental and clinical evaluation. Phytother Res 7, 285289.CrossRefGoogle Scholar
39Patel, JC, Dhirawani, MK & Doshi, JC (1968) ‘Karella’ in the treatment of diabetes mellitus. Indian J Med Sci 22, 3032.Google ScholarPubMed
40Khanna, P, Jain, SC, Panagariya, A, et al. (1981) Hypoglycemic activity of polypeptide-p from a plant source. J Nat Prod 44, 648655.CrossRefGoogle ScholarPubMed
41Akhtar, MS (1982) Trial of Momordica charantia Linn (Karela) powder in patients with maturity-onset diabetes. J Pak Med Assoc 32, 106107.Google ScholarPubMed
42Welihinda, J, Karunanayake, EH, Sheriff, MH, et al. (1986) Effect of Momordica charantia on the glucose in maturity onset diabetes. J Ethnopharmacol 17, 277282.CrossRefGoogle ScholarPubMed
43Grover, JK & Gupta, SR (1990) Hypoglycemic activity of seeds of Momordica charantia. Eur J Pharmacol 183, 10261027.CrossRefGoogle Scholar
44Ahmad, N, Hassan, MR, Halder, H, et al. (1999) Effect of Momordica charantia (Karolla) extracts on fasting and postprandial serum glucose in NIDDM patients. Bangladesh Med Res Counc Bull 25, 1113.Google ScholarPubMed
45Yeh, GY, Eisenberg, DM, Kaptchuk, TJ, et al. (2003) Systematic review of herbs and dietary supplements for glycemic control in diabetes. Diabetes Care 26, 12771294.CrossRefGoogle ScholarPubMed
46John, AJ, Cherian, R, Subhash, HS, et al. (2003) Evaluation of the efficacy of bitter gourd (Momordica charantia) as an oral hypoglycemic agent – a randomized controlled clinical trial. Indian J Physiol Pharmacol 47, 363365.Google ScholarPubMed
47Tongia, A, Tongia, SK & Dave, M (2004) Phytochemical determination and extraction of Momordica charantia fruit and its hypoglycemic potentiation of oral hypoglycemic drugs in diabetes mellitus (NIDDM). Indian J Physiol Pharmacol 48, 241244.Google Scholar
48Dans, AM, Villarruz, MV, Jimeno, CA, et al. (2007) The effect of Momordica charantia capsule preparation on glycemic control in type 2 diabetes mellitus needs further studies. J Clin Epidemiol 60, 554559.CrossRefGoogle ScholarPubMed
49Jadad, AR, Moore, RA, Carroll, D, et al. (1996) Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 17, 112.CrossRefGoogle ScholarPubMed
50Hulin, A (1988) Intoxication aigue par Momordica charantia (sorrossi). A propos de deux cas (Acute intoxication due to Momordica charantia (sorrossi). Study of two cases). Sem Hop 64, 28472848.Google Scholar
51Raman, A (1996) Anti-diabetic properties and phytochemistry of Momordica charantia L. (Cucurbitaceace). Phytomedicine 2, 349362.CrossRefGoogle Scholar
52Heiser, CB (1993) The Gourd Book. Norman, OK: University of Oklahoma Press.Google Scholar
53Stepka, W (1974) Antifertility investigations on Momordica. Lloydia 37, 645.Google Scholar
54Saksena, SK (1971) Study of antifertility activity of the leaves of Momordica Linn (Karela). Indian J Physiol Pharmacol 15, 7980.Google Scholar
55Dixit, VP, Khanna, P & Bhargava, SK (1978) Effects of Momordica charantia L. fruit extract on the testicular function of dog. Planta Med 34, 280286.CrossRefGoogle ScholarPubMed
56Chan, WY, Tam, PP & Yeung, HW (1984) The termination of early pregnancy in the mouse by β-momorcharin. Contraception 29, 91100.CrossRefGoogle ScholarPubMed
57Leung, SO, Yeung, HW & Leung, KN (1987) The immunosuppressive activities of two abortifacient proteins isolated from the seeds of bitter melon (Momordica charantia). Immunopharmacology 13, 159171.CrossRefGoogle Scholar
Figure 0

Table 1 Clinical studies of Momordica charantia (MC)

You have Access
108
Cited by

Save article to Kindle

To save this article to your Kindle, first ensure coreplatform@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about saving to your Kindle.

Note you can select to save to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

Anti-diabetic and hypoglycaemic effects of Momordica charantia (bitter melon): a mini review
Available formats
×

Save article to Dropbox

To save this article to your Dropbox account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you used this feature, you will be asked to authorise Cambridge Core to connect with your Dropbox account. Find out more about saving content to Dropbox.

Anti-diabetic and hypoglycaemic effects of Momordica charantia (bitter melon): a mini review
Available formats
×

Save article to Google Drive

To save this article to your Google Drive account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you used this feature, you will be asked to authorise Cambridge Core to connect with your Google Drive account. Find out more about saving content to Google Drive.

Anti-diabetic and hypoglycaemic effects of Momordica charantia (bitter melon): a mini review
Available formats
×
×

Reply to: Submit a response

Please enter your response.

Your details

Please enter a valid email address.

Conflicting interests

Do you have any conflicting interests? *